Closely held Dragonfleye Therapeutics has announced that it completed two non-brokered private placements of common shares during 2026, raising aggregate gross proceeds of $37.5 million. Participants included healthcare-dedicated investors and existing shareholders.
According to Dragonfleye, proceeds will fund continued development of the company’s ophthalmic treatments, expand the scope and depth of its platform technology, grow its partnership pipeline and intellectual property portfolio, advance regulatory and reimbursement strategies, and support working capital for general corporate purposes.
In a statement, Rajeev H. Muni, MD, FRCSC, co-founder and CEO of Dragonfleye, commented, “With this financing, we are one step closer to bringing our platform-based ocular treatments into clinical development. Our mission is to preserve and restore vision by treating eye diseases through a minimally invasive, versatile platform that provides nonsurgical, transscleral access to multiple ocular spaces, including the macula. The conviction shown by this group of new and existing investors reflects real confidence in our team, our science and engineering, and our goal of becoming a global leader in pioneering ocular treatments. We look forward to sharing our progress with stakeholders in the months ahead.”
